Bogacka E, Małolepszy J, Suchnicka R, Dawidiuk I
Katedry i Kliniki Chorób Wewnetrznych i Alergologii we Wrocławiu.
Pneumonol Alergol Pol. 1994;62(1-2):103-5.
One patients with nonatopic aspirin-sensitive asthma and another one with atopic asthma responding favourably to aspirin with a history of hydrocortisone intolerance were examined. The patients were challenged with intravenous, inhaled and oral hydrocortisone and its solvent. They showed significant fall of FEV1 after provocation tests with hydrocortisone but not after the solvent. Intradermal skin testing performed with hydrocortisone and its solvent was negative, what suggests that the intolerance to hydrocortisone was probably nonallergic feature. The patients tolerated well the intravenous challenge with prednisolone and oral challenge with prednisone, prednisolone and betamethasone. We suggest the replacement of intravenous hydrocortisone with these corticosteroids in the treatment of patients with hydrocortisone intolerance.
对一名非特应性阿司匹林敏感性哮喘患者和另一名对阿司匹林反应良好但有氢化可的松不耐受史的特应性哮喘患者进行了检查。对患者进行静脉注射、吸入和口服氢化可的松及其溶剂的激发试验。用氢化可的松进行激发试验后，他们的第一秒用力呼气量（FEV1）显著下降，但使用溶剂后未出现这种情况。用氢化可的松及其溶剂进行的皮内皮肤试验为阴性，这表明对氢化可的松的不耐受可能不是过敏特征。患者对泼尼松龙的静脉激发试验以及泼尼松、泼尼松龙和倍他米松的口服激发试验耐受性良好。我们建议在治疗氢化可的松不耐受的患者时，用这些皮质类固醇替代静脉注射氢化可的松。
